Bisphosphonate-related jaw necrosis - Severe complication in Maxillofacial surgery

Cancer Treatment Reviews

Volumn 33, Issue 1, 2007, Pages 58-63

  Eckert, A W ^a   Maurer, P ^a   Meyer, L ^a   Kriwalsky, M S ^a   Rohrberg, R ^b   Schneider, D ^a   Bilkenroth, U ^a   Schubert, J ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Praxis of Haematology and Oncology   (Germany)

Author keywords

Avascular jaw necrosis; Bisphosphonates; Bone metastasis

Indexed keywords

ALENDRONIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHLORHEXIDINE; GLUCOCORTICOID; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ACTINOMYCES; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; AVASCULAR NECROSIS; BACTERIAL INFECTION; BACTERIUM DETECTION; BREAST CANCER; CLINICAL ARTICLE; DENTAL SURGERY; EARLY DIAGNOSIS; ENDOPROSTHESIS; FEMALE; HUMAN; JAW DISEASE; LUNG CANCER; MALE; MULTIPLE MYELOMA; OSTEOPOROSIS; PROSTATE CANCER; REVIEW; SURGICAL TECHNIQUE; TOOTH EXTRACTION; TOOTH PROSTHESIS; WOUND CLOSURE;

BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; JAW; NECROSIS; RECURRENCE;

EID: 33846346245     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.09.003     Document Type: Review

References (31)

1. Saad F., Karakiewicz P., and Perrotte P. The role of bisphosphonates in hormone-refractory prostate cancer. World J Urol 23 1 (2005) 14-18
2. Coxon J.P., Oades G.M., Colston K.W., and Kirby R.S. Advances in the use of bisphosphonates in the prostate cancer setting. Prostate Cancer Prostatic Dis 7 2 (2004) 99-104
3. Saad F., Chi K., and Fleshner N. The role of bisphosphonate in the management of bone metastases in prostate cancer. Can J Urol 11 5 (2004) 2376-2382
4. Coleman R.E. The role of bisphosphonates in breast cancer. Breast 13 Suppl. 1 (2004) S 19-S 28
5. Lester J., and Coleman R. The use of bisphosphonates in breast cancer. J Br Menopause Soc 11 1 (2005) 12-17
6. Clemons M., and Verma S. Should oral bisphosphonates be standard of care in women with early breast cancer. Breast Cancer Res Treat 90 3 (2005) 315-318
7. Terpos E., and Rahemtulla A. Bisphosphonate treatment for multiple myeloma. Drugs Today 40 (2004) 29-40
8. Ashcroft A.J., Davies F.E., and Morgan G.J. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol 4 5 (2003) 284-292
9. Ural A.U., and Avcu F. Evolving therapeutic role of bisphosphonates in multiple myeloma. Br J Cancer 93 2 (2005) 267-268
10. Matsumoto S., Kimura S., Segawa H., Kuroda J., Yuasa T., Sato K., et al. Efficacy of their-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47 (2005) 31-39
11. Hoefert S., and Eufinger H. Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates. Mund Kiefer GesichtsChir 9 (2005) 233-238
12. Rogers M.J., Chilton K.M., Coxon F.P., Lawry J., Smith M.O., Suri S., et al. Bisphosphonates induce apoptosis in mouse macrophage-like in vitro by nitric oxide-independent mechanism. J Bone Miner Res 11 (1996) 1482-1491
13. Migliorati C.A. Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 99 2 (2005) 135
14. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
15. Melo M.D., and Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc 71 (2005) 111-113
16. Bagan J.V., Murillo J., Jimenez Y., Poveda R., Milian M.A., Sanchis J.M., et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 34 (2005) 120-123
17. Conte P.F., Giannessi P.G., Latreille J., et al. Delayed progression of bone metastases with pramidronate therapy in breast cancer patients: a randomized multicenter phase III trial. Ann Oncol 5 Suppl. 7 (1994) S41
18. Rodan G.A., and Fleisch H.A. Bisphosphonates: mechanisms of action. J Clin Invest 97 (1996) 2692-2696
19. Green J.R. Bisphosphonates: preclinical review. Oncologist 9 Suppl (2004) 3-13
20. Marx R.E. Pramidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing development. J Oral Maxillofac Surg 61 (2003) 1115-1117
21. Wang J., Goodger N.M., and Pogrel M.A. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61 (2003) 1104-1107
22. Schirmer I., Peters H., Reichart P.A., and Dürkop H. Bisphosphonates and osteonecrosis of the jaw. Mund Kiefer GesichtsChir 9 (2005) 239-245
23. Tarassoff P., and Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 61 (2003) 1238-1239
24. Hellstein J.W., and Marek C.L. Bisphosphonate osteochemonecrosis (Bis-Phossy jaw): is this phossy jaw of the 21st century. J Oral Maxillofac Surg 63 (2005) 682-689
25. Lin J.H., Rusell R.G., and Gertz B. Pharmacokinetics of alendronate: an overview. Int J Clin Pract 101 (1999) 18-26
26. O'Conell M.B., and Elliot M.E. Osteoporosis and osteomalacia. In: DiPiro T. (Ed). Pharmacotherapy: a pathophysiologic approach. 5th ed. (2002), McGraw-Hill, New York (NY) 1690
27. Durie B.G.M., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 7 (2005) 99-100
28. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
29. Badros A., Weikel D., Salama A., Goloubeva O., Schneider A., Rapoport A., et al. Osteonecrosis of the jaw in multiple myeloma patients clinical features and risk factors. J Clin Oncol 24 (2006) 945-952
30. Hoc S. Zoledronsäure schützt den Knochen effektiv. Dtsch Ärztebl 43 (2004) 2904
31. Acero J., Calvo de Mora J., Pujol R., Herencia H., Garcia Recuero I., Crespo J.L., et al. Maxillary necrosis associated with bisphosphonates. Presentation of four new cases. Int J Oral Maxillofac Surg 34 Suppl. 1 (2005) 139